Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

European Research Council grant · Finished

GRASP Antagonizing GnRH signaling as a “holistic” therapeutic strategy for Polycystic Ovary Syndrome

Coordinator
Institut National De La Sante Et De La Recherche Medicale, France
Runs
1 September 2023 to 28 February 2025
Status
Finished
EU funding
€150k
Total cost
—
Partners
2 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101111874

What the project is doing

In the project's own words, from its summary on CORDIS.

PCOS is the most common endocrine disorder affecting up to 18% of women worldwide. The syndrome imposes a heavy health burden, covering infertility, obesity, type 2 diabetes and metabolic syndrome. The development of treatment options is an urgent need since there is currently neither a cure nor mechanism-based treatments, leaving patient management suboptimal and focused solely on symptomatic treatment. One key neuroendocrine aberration in most women with PCOS is increased luteinizing hormone (LH) pulse frequency.

This suggests an increase in activity of gonadotropin-releasing hormone (GnRH) neurons in the hypothalamus. The LH hyper-pulsatility contributes to increased ovarian thecal androgen secretion and failure of ovulation, constituting a pivotal pathogenic role in the syndrome. These evidences suggest that alterations of GnRH neuronal activity/secretion could be the basis for neuroendocrine anomalies that accompany the reproductive disturbances in the syndrome.

In GRASP we will test the hypothesis that low administration doses of a GnRH antagonist, aimed at tempering LH secretion/pulsatility, can ameliorate both reproductive and metabolic PCOS traits in animal models of PCOS and in women with PCOS. The specific objectives of GRASP are to i) dose-range GnRH antagonism to rectify LH pulse amplitude and frequency in PCOS-like mice ; ii) to perform a long-term treatment with the selected doses of GnRH antagonist to assess its potential beneficial outcomes in correcting reproductive and metabolic alterations of this preclinical model; iii) to perform a pilot dose-effect clinical investigation testing the ability of sub-therapeutic doses of GnRH antagonist to rectify the altered hormonal dynamics in women with PCOS.

The overall goal of GRASP is to provide a proof-of-concept for future long-duration randomized controlled trials of this approach to appraise its clinical benefits in women with PCOS and to move forward towards therapeutic innovation.

Topics

Who is involved

OrganisationCityCountryRole
Institut National De La Sante Et De La Recherche MedicaleParisFranceCoordinator
Centre Hospitalier Regional Et Universitaire De LilleLilleFranceThird party

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI